Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cytokinetics, Inc.    CYTK

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

CYTOKINETICS : Announces Phase I and Phase IIa Clinical Trial Results for Omecamtiv Mecarbil Published in the Journal Lancet

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/19/2011 | 02:40pm CEST
Results from These Trials Form the Basis For Ongoing Phase IIb Activities in Collaboration with Amgen

South San Francisco, CA - August 19, 2011

omecamtiv mecarbil, a novel cardiac myosin activator, in the August 20, 2011 issue of the journal Lancet. These two manuscripts present data regarding the safety, tolerability, pharmacokinetics and pharmacodynamic effects of this investigational drug candidate from a Phase I first-time-in-humans clinical trial in healthy volunteers and a Phase IIa clinical trial in stable heart failure patients, each sponsored by Cytokinetics. Together, these publications provide evidence for the translation into humans of this unique mechanistic approach to activating cardiac muscle contractility and support the further development of omecamtiv mecarbil as a potential treatment for heart failure. Amgen Inc. holds an exclusive, worldwide (excluding Japan) license to omecamtiv mecarbil and related compounds, subject to specified development and commercialization participation rights of Cytokinetics.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CYTOKINETICS, INC.
05/19 CYTOKINETICS, INCORPORATED (NASDAQ : CYTK) Files An 8-K Submission of Matters to..
05/19 CYTOKINETICS INC : Submission of Matters to a Vote of Security Holders (form 8-K..
05/16 CYTOKINETICS : CYTK) Receives FDA Orphan Drug Designation for CK-2127107 for Tre..
05/15 CYTOKINETICS INC : Other Events (form 8-K)
05/15 Cytokinetics Announces Orphan Drug Designation for CK-2127107 for the Treatme..
05/11 Cytokinetics to Hold Annual Meeting of Stockholders
05/10 CYTOKINETICS : Announces Pricing of Public Offering of Common Stock
05/09 CYTOKINETICS, INCORPORATED (NASDAQ : CYTK) Files An 8-K Other Events
05/09 CYTOKINETICS INC : Other Events, Financial Statements and Exhibits (form 8-K)
05/09 Cytokinetics Announces Pricing of Public Offering of Common Stock
More news
Sector news : Bio Therapeutic Drugs
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJAMGEN : Another Gloomy Day for Amgen
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/09DJVERTEX PHARMACEUTICALS INCORPORATED : Trump's Pick to Lead FDA Has Backing of Bi..
More sector news : Bio Therapeutic Drugs
Advertisement
Financials ($)
Sales 2017 28,0 M
EBIT 2017 -96,4 M
Net income 2017 -103 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 24,3x
Capi. / Sales 2018 12,2x
Capitalization 681 M
More Financials
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 21,7 $
Spread / Average Target 55%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Robert I. Blum President, Chief Executive Officer & Director
L. Patrick Gage Chairman
Barabari Sharon A. Surrey Chief Financial Officer, Secretary & Executive VP
Andrew A. Wolff Chief Medical Officer & Senior Vice President
Fady Ibraham Malik Executive Vice President-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CYTOKINETICS, INC.694
AMGEN, INC.5.38%112 531
CELGENE CORPORATION1.35%90 349
GILEAD SCIENCES, INC.-9.66%84 101
REGENERON PHARMACEUTIC..25.58%48 999
ACTELION LTD25.17%30 824
More Results